Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEM: Semaglutide for Methamphetamine Use Disorder
NCT07204249Phase 2Recruiting
- Sponsor
- San Francisco Department of Public Health
- Start
- Feb 2026
- Primary completion
- Feb 2030
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide in methamphetamine use disorder (MUD), sponsored by San Francisco Department of Public Health. Started Feb 2026; status: recruiting.
02
Drugs
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on NCT07204249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07204249.